News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor
Pashtoon Kasi/LinkedIn
Jul 10, 2025, 20:08

Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor

Pashtoon Kasi, Medical Director at City of Hope, shared on LinkedIn:

“Published today JCOPO, American Society of Clinical Oncology (ASCO)

The 1st agnostic study of a PARP inhibitor:

LODESTAR: Rucaparib

Need to think about variants in Homologous Recombination Repair (HRR) Genes beyond canonical BRCA PALB2.

Novel insights. Years of effort.”

Pashtoon Kasi

Title: LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes

Authors: Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey I. Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B. Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss

Read full article.

Pashtoon Kasi

(JCOPO) Alexa B. Schrock ASCO Brennan Decker cancer Doug E. Laux E. Gabriela Chiorean Ethan S Sokol Gary K. Schwartz Geoffrey I Shapiro Hanna Tukachinsky HRR Karen McLachlan Katherine L. Nathanson Kevin K. Lin Kim A. Reiss Lara Maloney Maen Hussein Marcia Craib Nicholas J. Seewald OncoDaily Oncology Pashtoon Kasi Pashtoon Murtaza Kasi Shuoguo Wang Sriram Anbil Susan M. Domchek
Special Coverage
Insight
Jul 10, 2025, 20:08
Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor
Drugs
Jul 10, 2025, 16:59
Taletrectinib (Ibtrozi): What Patients Should Know About in 2025?
Blog
Jul 10, 2025, 16:30
Indiana’s First Mobile Lung Screening Unit Proves That Access to Care Saves Lives - IU Simon Comprehensive Cancer Center
Blog
Jul 10, 2025, 16:24
Herbert Loong: Had an Opportunity to Introduce and Discuss Soft Tissue Sarcomas at Radio Television Hong Kong
Blog
Jul 10, 2025, 16:14
Sebastian Other-Gee Pohl Completed 2 Years of EACR-Boehringer Ingelheim Postdoctoral Fellowship
Blog
Jul 10, 2025, 16:11
Heba Bakri: Honored to Welcome Assiut University Heamtology Team for a Discussion on Multiple Myeloma Management
Blog
Jul 10, 2025, 16:00
Mahul B Amin: Honored to Contribute 11th Edition of Robbins and Cotran Pathology Textbook
Science
Jul 10, 2025, 15:44
Justin Yeung: Patient Reported Outcome Measures in the Treatment of Colorectal Cancer
Celebrities
Jul 10, 2025, 15:23
King Albert II’s Brave Battle: A Decade of Fighting Skin Cancer
Oncolibrary
Jul 10, 2025, 15:13
Bladder Cancer Chemotherapy Success Rate: What Patients Need to Know in 2025
Science
Jul 10, 2025, 15:12
Luisa Soares Miranda: Excited to Share our Latest Publication on Trastuzumab Deruxtecan in Previously Treated HER2-Low MBC
Blog
Jul 10, 2025, 15:11
Francisco J Esteva: Post-Chemo Weight Gain - Fight Back For Your Health and Confidence